|
1）Drachman DB. Myasthenia gravis. N Engl J Med. 1994; 330: 1797-810
|
|
|
|
2）Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001; 7: 365-8
|
|
|
|
|
|
3）Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in ʻseronegativeʼ myasthenia gravis. Brain. 2008; 131(Pt 7): 1940-52
|
|
|
|
|
|
4）Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011; 69: 418-22
|
|
|
|
|
|
5）Higuchi O. Autoantibodies to low-density lipoprotein receptor-related protein 4 that is essential for the neuromuscular junction formation. Clin Exp Neuroimmunol. 2013; 4: 216-9
|
|
|
|
|
|
6）Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci. 2001; 2: 791-805
|
|
|
|
|
|
7）Ramarao MK, Bianchetta MJ, Lanken J, et al. Role of rapsyn tetratricopeptide repeat and coiled-coil domains in self-association and nicotinic acetylcholine receptor clustering. J Biol Chem. 2001; 276: 7475-83
|
|
|
|
|
|
8）Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol. 2012; 69: 994-1001
|
|
|
|
|
|
9）Rodríguez Cruz PM, Al-Hajjar M, et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol. 2015; 72: 642-9
|
|
|
|
|
|
10）Zhao G, Wang X, Yu X, et al. Clinical application of clustered-AChR for the detection of SNMG. Sci Rep. 2015; 5: 10193
|
|
|
|
|
|
11）Devic P, Petiot P, Simonet T, et al. Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol. 2014; 21: 130-4
|
|
|
|
|
|
12）Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013; 123: 5190-202
|
|
|
|
|
|
13）Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014; 52: 139-45
|
|
|
|
|
|
14）Tzartos JS, Zisimopoulou P, Rentzos M, et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014; 1: 80-7
|
|
|
|
|
|
15）Ohta K, Shigemoto K, Fujinami A, et al. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol. 2007; 14: 1029-34
|
|
|
|
|
|
16）Murai H, Masuda M, Utsugisawa K, et al. Clinical features and treatment status of adult myasthenia gravis in Japan. Clin Exp Neuroimmunol. 2014; 5: 84-91
|
|
|
|
|
|
17）Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013; 110: 20783-8
|
|
|
|
|
|
18）Ohkawara B, Cabrera-Serrano M, Nakata T, et al. LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. Hum Mol Genet. 2014; 23: 1856-68
|
|
|
|
|
|
19）Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology. 2011; 77: 1819-26
|
|
|
|
|
|
20）Zoltowska Katarzyna M, Belaya K, et al. Collagen Q--a potential target for autoantibodies in myasthenia gravis. J Neurol Sci. 2015; 348: 241-4
|
|
|
|
|
|
21）Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One. 2014; 9: e91816
|
|
|
|
|
|
22）Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology. 2014; 82: 1976-83
|
|
|
|
|